Reading ACHV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACHV free→Reading ACHV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACHV free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality cannot be assessed since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. The market mood is heating. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $5.52. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.87x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.33 → $-0.15 (+54.5% / 30d). 6 raised, 0 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$266.
How much price usually moves either way.
On a bad day, this stock has moved -$643.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,455.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If health care revenue growth speeds up, it may support Achieve's recovery.
Confirms:Health care sector revenue growth is speeding up toward 10% or more.
Disproves:Revenue growth keeps slowing down below 10%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for ACHV yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Board Members On May 29, 2026, the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date. Mr. Marrow has also been appointed to the Nominating and Governance Committee of the Board as a…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
ACHV Achieve Life Sciences Inc | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 77 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Achieve Life Sciences aims to secure funding through a private placement to support its operations.
Newly stated in 2026-Q1. The company announced a private placement for gross proceeds up to $354 million to support its operations. This is a new initiative, and its success will depend on the completion of the placement.
“The company announced a private placement for gross proceeds up to approximately $354 million.”
Focus on managing and reducing net income losses to improve financial stability.
Stated in 4 of last 4 quarters. Net income loss decreased from $14.66 million in 2025-Q4 to $10.17 million in 2026-Q1. The company is making progress in reducing losses, indicating a positive trajectory in managing costs.
“Net income was reported as a loss of $10.17 million.”
“Net income was reported as a loss of $14.66 million.”
“Net income was reported as a loss of $14.44 million.”
“Net income was reported as a loss of $12.72 million.”
Focus on improving cash flow from operations to enhance liquidity.
Stated in 4 of last 4 quarters. Cash flow from operations improved from negative $17.98 million in 2025-Q4 to negative $6.93 million in 2026-Q1. The company is showing progress in enhancing liquidity, though it remains negative.
“Cash flow from operations was negative $6.93 million.”
“Cash flow from operations was negative $17.98 million.”
“Cash flow from operations was negative $11.33 million.”
“Cash flow from operations was negative $9.07 million.”
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Appointment of Board Member In connection with the previously reported private placement (the “Private Placement”) of the Company’s securities, and pursuant to the designation right granted to Frazier Life Sciences, on May 11, 2026, the Company’s board of directors (the “Board”) appointed Christopher Martin to serve as a director of the Company, e…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Departure of Chief Executive Officer In connection with the Private Placement, on April 15, 2026, Richard Stewart, the Company’s Chief Executive Officer and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s Chief Executive Officer, President and “principal executive…
Entry into a Material Definitive Agreement . Securities Purchase Agreement On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock,…